SNORD114-28: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORD114-28

NCBI ID: G767609

SNORD114-28

Other Name(s): small nucleolar RNA, C/D box 114-28 | 14q(II-28) | Small nucleolar RNA, C/D box 114-28

SNORD114-28: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known snRNAs is SNORD114-28, which is a 28-nt RNA molecule located within the C/D box of RNA polymerase II (RNA-II) gene. The C/D box is a region of the snRNA molecule that contains a conserved core and a variable region. The conserved core is responsible for the stability and structure of the snRNA, while the variable region is involved in the recognition of specific sequences in the DNA.

SNORD114-28 is a well-characterized snRNA that has been shown to play important roles in various cellular processes, including cell growth, cell cycle progression, and DNA replication. One of the most significant functions of SNORD114-28 is its role in regulating the expression of genes involved in cell growth and differentiation. For example, studies have shown that SNORD114-28 can interact with the transcription factor, p53, to prevent the translation of certain genes into proteins and to promote the translation of others.

Another function of SNORD114-28 is its role in the regulation of cell cycle progression. Studies have shown that SNORD114-28 is involved in the regulation of the G1/S transition, which is the critical stage of cell cycle progression where genes are expressed and the cell prepares for cell division. During the G1/S transition, SNORD114-28 is known to interact with the transcription factor, p21, to promote the expression of genes involved in cell growth and differentiation.

In addition to its role in cell cycle progression, SNORD114-28 is also involved in the regulation of DNA replication. Studies have shown that SNORD114-28 can interact with the transcription factor, RNP1, to promote the loading of RNA polymerase II onto the replicating DNA strand. This interaction between SNORD114-28 and RNP1 is critical for the initiation of DNA replication and for the production of new DNA molecules.

SNORD114-28 has also been shown to play a role in the regulation of cellular signaling pathways. For example, studies have shown that SNORD114-28 can interact with the transcription factor, NF-YB, to promote the translation of certain genes into protein and to inhibit the translation of others. This interaction between SNORD114-28 and NF-YB is critical for the regulation of cellular signaling pathways and for the production of specific proteins involved in these pathways.

Furthermore, SNORD114-28 has also been shown to play a role in the regulation of gene expression in cancer. Studies have shown that SNORD114-28 can be overexpressed or downregulated in cancer cells, which can lead to the translation of certain genes into proteins and the inhibition of others. This overexpression or downregulation of SNORD114-28 can contribute to the development of cancer and to the progression of disease.

In conclusion, SNORD114-28 is a well-characterized small nucleolar RNA that plays a critical role in the regulation of various cellular processes, including cell growth, cell cycle progression, DNA replication, and signaling pathways. Its functions as a drug target or biomarker make it an attractive target for further study and potential therapeutic intervention. Further research is needed to fully understand the mechanisms of action of SNORD114-28 and to develop effective treatments for the regulation of cellular processes

Protein Name: Small Nucleolar RNA, C/D Box 114-28

The "SNORD114-28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets